ERBB2 and metastatic malignant neoplasm: However, trastuzumab-deruxtecan, a newer trastuzumab-drug conjugate, demonstrated an efficacy in some patients with HER2-negative metastatic cancers [29]; this efficacy signal is now investigated in a phase 3 trial (NCT03734029).